ABVXABIVAX Société Anonyme

$118.93

$68.9652 weeks$145.31

Latest close: back above its 200-day averageSep 8, 2026what changed →

Price

$118.93+70%1Y

1M-8.5%1Y+70%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Below average

3/10

Value75

Quality10

Momentum51

Growth9

Strongest Value, weakest Growth · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. We focus on indications where existing treatments have left patients with significant unmet needs, and where we believe our investigational agents have the potential to be meaningfully differentiated from currently available therapies.

In the company’s own words · 20-F filed Mar 23, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$7.36B

1Y Return+70%

5Y Return-

For the full year FY2025, revenue was €5.6M (−55% year on year) and net income −€336M.